SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: William Partmann who wrote (778)12/23/1999 10:02:00 AM
From: William Partmann  Read Replies (1) | Respond to of 10345
 
From Briefing,

07:50 ET ELAN CORP (ELN) 25 3/8: Merrill Lynch reiterates "buy" and says ELN remains top pick for the year 2000; Merrill is confident that ELN will file its NDA for ziconotide, to treat refractory pain, before year end; believes 1999 revenue should reach $1 bln, which is two years ahead of the co's target; says the stock's P/E is well below peer group and is at a significant discount to projected growth\